16.03

0.57% 0.11

Kura Oncology Inc (KURA)

Overview News Price History Option Chain Financials Discussions Forecast

Kura Oncology Inc stock is traded at $16.03, with a volume of 283.07K. It is up +0.57% in the last 24 hours and down -11.06% over the past month. Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

Previous Close:

$15.92

Open:

$15.99

24h Volume:

283.07K

Relative Volume:

0.52

Market Cap:

$1.21B

Revenue:

Net Income/Loss:

$-168.09M

P/E Ratio:

-7.8195

EPS:

-2.05

Net Cash Flow:

$-138.01M

1W Performance:

-8.83%

1M Performance:

-11.06%

6M Performance:

-27.79%

1Y Performance:

+67.47%

1-Day Range:

$15.75

$16.68

1-Week Range:

$15.55

$19.73

52-Week Range:

$9.06

$24.17

Kura Oncology Inc Stock (KURA) Company Profile

Name

Kura Oncology Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(858) 500-8800

Address

12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA

Employee

142

Twitter

@kuraoncology

Next Earnings Date

2024-11-07

Latest SEC Filings

KURA's Discussions on Twitter

Compare KURA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KURA	16.00	1.21B	0	-168.09M	-138.01M	-2.05
VRTX	467.40	119.83B	10.63B	-479.80M	-1.35B	13.33
REGN	760.64	83.28B	13.85B	4.65B	3.32B	35.06
ARGX	565.93	33.74B	1.86B	-40.29M	-1.28B	-4.16
ALNY	230.33	30.38B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.13	24.08B	3.30B	-501.07M	1.03B	11.54

Kura Oncology Inc Stock (KURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-22-23	Initiated	Mizuho	Buy
Aug-11-23	Initiated	BofA Securities	Buy
Jul-27-23	Initiated	Scotiabank	Sector Perform
May-17-23	Initiated	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight
Feb-15-22	Initiated	Jefferies	Buy
May-05-21	Resumed	Credit Suisse	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Dec-07-20	Reiterated	H.C. Wainwright	Buy
Dec-03-20	Initiated	Stifel	Buy
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform
May-05-20	Initiated	Barclays	Overweight
Jul-18-19	Initiated	Deutsche Bank	Buy
Nov-09-18	Initiated	Piper Jaffray	Overweight
Aug-01-18	Initiated	H.C. Wainwright	Buy
Oct-13-16	Resumed	Leerink Partners	Outperform
Jan-22-16	Initiated	JMP Securities	Mkt Outperform
Dec-30-15	Initiated	Oppenheimer	Outperform
Dec-16-15	Initiated	Citigroup	Buy

View All

Kura Oncology Inc Stock (KURA) Latest News

07:56 AM

Kura Oncology stock gains spotlight amid Revuforj's FDA approval By Investing.com - Investing.com UK

07:56 AM

Nov 16, 2024

Objective long/short (KURA) Report - Stock Traders Daily

Nov 16, 2024

Nov 15, 2024

Paradigm Biocapital Advisors LP Adjusts Stake in Kura Oncology I - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Kura Oncology (NASDAQ:KURA) Raised to “Hold” at StockNews.com - Defense World

Nov 14, 2024

Nov 13, 2024

Kura Oncology's SWOT analysis: ziftomenib drives stock potential amid AML market - Investing.com Australia

Nov 13, 2024

HC Wainwright Reiterates "Buy" Rating for Kura Oncology (NASDAQ:KURA) - MarketBeat

Nov 13, 2024

Nov 11, 2024

Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Call Transcript - MSN

Nov 11, 2024

FY2026 EPS Estimate for Kura Oncology Lifted by Analyst - MarketBeat

Nov 11, 2024

Nov 10, 2024

HC Wainwright Reaffirms Buy Rating for Kura Oncology (NASDAQ:KURA) - Defense World

Nov 10, 2024

Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Price Target at $28.83 - MarketBeat

Nov 10, 2024

Nov 08, 2024